P4A Let's Talk Rare: The Life Science Podcast · Partners4Access

2026 Trends: A Year Of Change & Opportunity

·17 min·1 clip

Pharma companies cannot treat Europe and the U.S. as separate sequential decisions anymore due to JCA and MFN pricing interconnections.

This episode analyzes two major 2026 trends in life sciences market access: the implementation of Europe's Joint Clinical Assessment (JCA) for oncology and ATMP products, and the impact of US Most Favoured Nation (MFN) pricing that links US drug prices to international benchmarks. Experts from Partners for Access explain how these interconnected forces require pharmaceutical companies to develop integrated global strategies rather than treating regions separately.

As heard by us

JCA and MFN become launch realities, not just policy noise.

This episode is strongest when it treats Europe's JCA and US MFN pricing as live market-access pressure rather than abstract policy. It connects that pressure to launch sequencing, global price corridors, dossier quality, and market selection in a way that feels grounded and…

Read the full review in PlayNext →

Why you'd press play

You need a quick read on JCA and MFN before a launch meeting.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from P4A Let's Talk Rare: The Life Science Podcast